secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-002398
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B
--------------------------------------------------------------------------------

- Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.
- Tiered royalties on net sales from high single digit to low-teen percentages per licensed product.
- Moderna gets exclusive worldwide license to CytomX Probody platform for mRNA-encoded conditionally-activated therapies.
- Moderna has a one-time option to participate in a future CytomX equity financing.
- Collaboration covers oncology and non-oncology programs; Moderna can terminate on product-by-product basis after 2 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/0001193125-23-002398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/d405031d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer